Peptide-based drugs targeting the brain's reward, stress, and craving pathways show promising potential in animal studies for reducing alcohol use and preventing relapse, with early clinical trials underway.
4 peptide systems targetedPeptide therapies for alcohol addiction target four distinct neuronal pathways — opioid, CRF, NPY, and glutamate — each addressing a different aspect of the addiction cycle from reward to stress to craving.
What the researchers found
Preclinical research demonstrates that peptide-based therapies targeting four major neuronal systems — opioid, corticotropin-releasing factor (CRF), neuropeptide Y (NPY), and glutamate — can reduce alcohol intake, demand, and relapse in animal models of alcohol use disorder. Opioid peptides (β-endorphin, enkephalins) modulate alcohol reward via µ, δ, and κ receptors; CRF peptides reduce stress-driven alcohol seeking; and NPY peptides decrease cravings and anxiety. Early clinical trial results show translational potential, though challenges remain in establishing safety and efficacy in humans.
Why it matters
Alcohol use disorder affects millions of people worldwide but has very few approved pharmacological treatments. Peptide-based therapies offer a fundamentally different approach by precisely targeting the specific brain pathways that drive addiction — reward processing, stress responses, and craving — rather than using broad-acting drugs with significant side effects.
How the study worked
This is a narrative review synthesizing preclinical research on peptide-based interventions for alcohol use disorder, covering opioid peptides, CRF peptides, NPY, and glutamate system modulators. The review evaluates animal model data and early clinical trial results, and discusses translational challenges.
Who was studied
Review covering preclinical animal models and early human clinical trials for alcohol use disorder
What this study cannot tell us
As a narrative review, this article does not include systematic search methodology or meta-analysis. Most evidence discussed comes from animal models, and the translational gap between preclinical and clinical results remains significant. Specific clinical trial outcomes and effect sizes are not detailed in the abstract. Pharmacokinetic challenges of peptide delivery to the brain are acknowledged but not resolved.
How to read the evidence
This is a narrative review summarizing preclinical animal data and early clinical trials. While it provides a comprehensive overview of the field, most evidence comes from animal models and the review lacks systematic methodology. The translational evidence remains preliminary.
When this study was published
Published in 2025, this is a very current review capturing the latest developments in peptide pharmacology for alcohol use disorder, including recent early-phase clinical trial data.
The bigger picture
Current FDA-approved treatments for alcohol use disorder (naltrexone, acamprosate, disulfiram) have limited effectiveness and significant side effects. Peptide pharmacology represents an emerging precision medicine approach to addiction, targeting the specific neurobiological mechanisms that sustain the disorder rather than broadly dampening brain chemistry. If peptide delivery challenges can be solved, this class of drugs could significantly expand treatment options for the millions of people living with alcohol addiction.
Questions still open
- Which of the four peptide systems — opioid, CRF, NPY, or glutamate — offers the most promising clinical translation for AUD treatment?
- Can peptide drugs overcome the blood-brain barrier and pharmacokinetic challenges required for effective brain delivery?
- Could combination therapies targeting multiple peptide systems simultaneously be more effective than single-target approaches?
Common questions
Why don't current alcohol addiction medications work well enough?
How would peptide drugs for alcohol addiction actually work in the brain?
Read the original research
Peptide pharmacology: Pioneering interventions for alcohol use disorder.
Progress in molecular biology and translational science, 212, 117-128
Citation
Katturajan, Ramkumar; Evan Prince, Sabina; Valsala Gopalakrishnan, Abilash. (2025). Peptide pharmacology: Pioneering interventions for alcohol use disorder.. Progress in molecular biology and translational science, 212, 117-128. https://doi.org/10.1016/bs.pmbts.2024.05.003